Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Distigmine→

Distigmine Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
17299-00-2
Molecular formula
C22H32N4O4+2
Molecular weight
416.5 g/mol
Drug class
Long-acting reversible acetylcholinesterase inhibitorquaternary ammonium carbamate
Mechanism of action
Reversibly inhibits acetylcholinesterase, increasing acetylcholine concentrations at cholinergic synapses and enhancing neuromuscular transmission and parasympathetic activity.
Indications / reported uses
  • Treatment of myasthenia gravis in product-authorised jurisdictions
  • Treatment of underactive bladder/urinary retention due to detrusor hypocontractility in specific countries and formulations; local product information must be checked

Sources: NLM MeSH — Distigmine · PubMed clinical pharmacology search · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Distigmine Environmental Risk Assessment (ERA) (the Distigmine ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.